imatinib mesylate has been researched along with Pulmonary Arterial Hypertension in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, LL; Clemons, B; Douthitt, A; Galkin, A; Gandjeva, A; Garcia, E; Guimond, D; Kennedy, M; Osterhout, R; Salter-Cid, L; Sitapara, R; Slee, D; Tuder, RM; Zisman, LS | 1 |
| Akaki, K; Asano, R; Hia, F; Inagaki, T; Ishibashi, T; Ishibashi-Ueda, H; Manabe, Y; Masaki, T; Mino, T; Mori, H; Morinobu, A; Morita, S; Nakaoka, Y; Nakatsuka, Y; Ogo, T; Okazawa, M; Sato, A; Takeuchi, O; Tsujimura, T; Uehata, T; Vandenbon, A; Yaku, A; Yoshinaga, M | 1 |
| Akagi, S; Ejiri, K; Ito, H; Matsubara, H; Miyoshi, T; Nakagawa, K; Nakamura, K; Takaya, Y; Toh, N; Yoshida, M | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
1 review(s) available for imatinib mesylate and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Delivery Systems; Humans; Imatinib Mesylate; Nanoparticles; Pulmonary Arterial Hypertension; Quinolines | 2019 |
3 other study(ies) available for imatinib mesylate and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Topics: Animals; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; MicroRNAs; Monocrotaline; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats | 2022 |
Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Topics: Animals; Biomarkers; Cytokines; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Imatinib Mesylate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Leukocytes, Mononuclear; Macrophages, Alveolar; Mice; Platelet-Derived Growth Factor; Pulmonary Arterial Hypertension; Pulmonary Artery; Ribonucleases; RNA Stability; Vascular Remodeling | 2022 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |